Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AO-252 |
Synonyms | |
Therapy Description |
AO-252 is a TACC3 protein-protein interaction inhibitor, which potentially decreases tumor growth (Cancer Res (2023) 83 (7_Supplement): 1664). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AO-252 | AO252|AO 252 | AO-252 is a TACC3 protein-protein interaction inhibitor, which potentially decreases tumor growth (Cancer Res (2023) 83 (7_Supplement): 1664). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06136884 | Phase I | AO-252 | A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors | Recruiting | USA | 0 |